GeneDx Holdings Profit Margin

The latest profit margin for WGS is -23.4% as of June 2026. That compares with 0.39% in the prior-year period — down 6131.3% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside GeneDx Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, WGS's profit margin moved from 0.39% to -23.4% — a 6131.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneDx Holdings's valuation or profitability profile.

Against Healthcare companies, WGS currently prints -23.4% for profit margin, while the sector average sits near 14.34%. That is roughly 263.2% below the sector mean. Large gaps often invite a closer look at GeneDx Holdings's growth, margins, and balance sheet.

Profit Margin shows how effectively GeneDx Holdings converts resources into returns. At -23.4%, WGS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 0.39% in the prior-year period — down 6131.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting WGS's profit margin (-23.4%), review year-over-year change from 0.39%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.